Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L12 (RPL12) is a structural protein that forms part of the large (60S) subunit of the eukaryotic ribosome, which functions as the cellular machinery for protein synthesis[2][3]. It binds directly to 26S rRNA and is located in the cytoplasm. RPL12 is imported into the nucleus by a distinct transport pathway mediated by importin 11, rather than the general importin system utilized by most ribosomal proteins[1]. This specialized pathway may serve to regulate ribosome assembly and maturation[1]. RPL12 belongs to the L11P family of ribosomal proteins and is evolutionarily conserved. Mutations or defects in RPL12 may be linked to disorders of ribosomal function, such as Diamond-Blackfan anemia[3]. There are currently no drugs that directly target this protein, and its ubiquitous essential role means that direct targeting would likely be toxic to normal cells.
Not applicable; no direct human drugs target RPL12. In bacteria, some antibiotics indirectly interfere with proteins analogous to L12, but this is outside human therapeutics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L12 (RPL12).